Suchergebnisse - "Komrokji, Rami"

PubPharm (474)

1

Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML

enthalten in: Annals of hematology | 2024

von Jain, A. | Gesiotto, Q. | Ball, S. | +10

2

TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q)

enthalten in: British journal of haematology | 2024

von Tefferi, A. | Fleti, F. | Chan, O. | +18

3

Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib

enthalten in: JCO precision oncology | 2024

von Kuykendall, A. | Ball, S. | Mora, B. | +12

4

Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML

enthalten in: Blood advances | 2024

von Chan, O. | Al Ali, N. | Tashkandi, H. | +19

5

Triple-Negative Myelofibrosis : Disease Features, Response to Treatment and Outcomes

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Aguirre, L. | Jain, A. | Ball, S. | +10

6

Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Chavez, J. | Grajales, A. | Sandoval-Sus, J. | +14

7

Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Ionescu, F. | David, J. | Ravichandran, A. | +15

8

Patterns of lower risk myelodysplastic syndrome progression : factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia

enthalten in: Haematologica | 2024

von Jain, A. | Ball, S. | Aguirre, L. | +10

9

Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities

enthalten in: Annals of hematology | 2024

von Horvat, N. | Abdallah, E. | Xie, Z. | +9

10

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge) : a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

enthalten in: Lancet (London, England) | 2024

von Platzbecker, U. | Santini, V. | Fenaux, P. | +21

ErratumIn: Lancet. 2024 Jan 20;403(10423):248. - PMID 38245245

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[48]